Emerald Advisers LLC Takes Position in Hinge Health Inc. $HNGE

Emerald Advisers LLC bought a new stake in shares of Hinge Health Inc. (NYSE:HNGE) in the second quarter, Holdings Channel reports. The fund bought 2,093 shares of the company’s stock, valued at approximately $108,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Strategic Blueprint LLC bought a new position in shares of Hinge Health during the 2nd quarter valued at approximately $346,000. FNY Investment Advisers LLC bought a new position in shares of Hinge Health during the 2nd quarter valued at approximately $310,000. Finally, CHURCHILL MANAGEMENT Corp bought a new position in shares of Hinge Health during the 2nd quarter valued at approximately $828,000.

Hinge Health Stock Down 2.8%

Shares of NYSE:HNGE opened at $49.53 on Thursday. The firm has a fifty day moving average price of $53.61. Hinge Health Inc. has a one year low of $33.42 and a one year high of $62.18.

Hinge Health (NYSE:HNGE) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($13.10) EPS for the quarter, missing the consensus estimate of ($4.98) by ($8.12). The business had revenue of $139.10 million for the quarter, compared to analysts’ expectations of $125.16 million. During the same period last year, the firm posted ($0.96) earnings per share. Hinge Health’s revenue for the quarter was up 54.9% on a year-over-year basis. Hinge Health has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS.

Wall Street Analysts Forecast Growth

HNGE has been the subject of several analyst reports. Citizens Jmp initiated coverage on shares of Hinge Health in a report on Monday, July 14th. They issued a “strong-buy” rating and a $58.00 price objective for the company. Robert W. Baird initiated coverage on shares of Hinge Health in a report on Friday, September 5th. They issued a “neutral” rating and a $56.00 price objective for the company. Bank of America raised their price objective on shares of Hinge Health from $42.00 to $64.00 and gave the stock a “buy” rating in a report on Wednesday, August 6th. Stifel Nicolaus raised their price objective on shares of Hinge Health from $63.00 to $66.00 and gave the stock a “buy” rating in a report on Thursday, September 11th. Finally, Morgan Stanley raised their price objective on shares of Hinge Health from $57.00 to $67.00 and gave the stock an “overweight” rating in a report on Tuesday, September 23rd. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $57.47.

Hinge Health Profile

Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.